US Oncologist Survey: Optimizing Treatment for Advanced Renal Cell Cancer


February 25, 2011
42 Pages - SKU: TAG6197087
License type:
Table of Contents Search inside this report Related Reports
Countries covered: United States
Treatment decisions for advanced stages of renal cell cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This series of reports will allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

Primary research for the oncology prescribing data that you are missing, directly from high-prescribing US oncologists: what they prescribe, when, and why. Case highlights include:
  • Older patient with retroperitoneal adenopathy and small lung nodules
  • Anemic patient with extremely high LDH levels
  • Patient with multiple comorbidities including heart and lung disease
  • Patient with one kidney and comorbidities
This report allows you to:
  • Understand what occurs in the oncologist’s office with actual patients
  • Access the most up-to-date prescribing trends and the factors that influence treatment decisions
  • Gain actionable data for developing and improving market strategies
  • Pinpoint the needs of your target audience to capitalize on opportunities that improve the position of your product
  • Design messages to advance brand performance and impact decisions
  • Focus your resources to maximize the effectiveness of your budget


Additional Information

Report Excerpt

Introduction

Renal cell carcinoma (RCC) is a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes in the kidney. Renal cell carcinoma is the most common type of kidney cancer in adults. It occurs most often in men aged 50 - 70. Sometimes both kidneys are involved. The cancer spreads easily, most often to the lungs and other organs. In about one-third of patients, the cancer has already spread at the time of diagnosis. About half of all cases of RCC are now found by chance when a person gets an imaging test for a different health issue. In these cases, the person might not have any noticeable signs or symptoms of RCC.

A cure is unlikely unless all of the cancer is removed with surgery. Of the people who are diagnosed with RCC, about 25% to 30% already have advanced disease when they are diagnosed. Although patients with early-stage disease can potentially be cured with surgery, many will either experience a recurrence after surgery, or have advanced disease at the time of initial presentation. The outcome depends on how much the cancer has spread and how well it responds to treatment. Possible complications include hypertension, high calcium levels, high red blood cell counts, and liver function abnormalities. Despite significant advances in treatment for advanced renal cell carcinoma, there remains a need to develop new, more effective therapies with improved tolerability.

RCC is generally resistant to standard chemotherapy, and radiation therapy usually does not work, so it is not often used. However, immunotherapeutic regimens have been widely used in patients with advanced disease. Recently, several anti-angiogenesis drugs have demonstrated clinical activity in patients with advanced or metastatic RCC. Although targeted therapies have advanced the treatment of metastatic RCC, complete and durable responses are not achieved in the majority of patients, and a need remains for new treatment options.
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Renal Cell Cancer
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Renal Cell Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of Good to Moderate Prognosis Renal Cell Cancer
Initial treatment regimen chosen following surgery
Figure 3.1
Other therapeutic agents that would be considered appropriate to include in therapy
Figure 3.2
Treatment decision for medication toxicity
Figure 3.3
Second-line therapy treatment
Figure 3.4
Factors influencing treatment
Figure 3.5
Third-line therapy treatment
Figure 3.6
Most important barrier to optimal patient management
Figure 3.7
Confidence in managing this patient
Figure 3.8
Chapter 4: Treatment of Patient with Poor Prognosis Renal Cell Cancer
Appropriate treatment regimen
Figure 4.1
Treatment regarding metabolic and laboratory abnormalities
Figure 4.2
Treatment choice for progressive disease
Figure 4.3
Chapter 5: Treatment of Patient with Multiple Comorbidities
Management of patient with COPD
Figure 5.1
Choice of systemic therapy agent
Figure 5.2
Tests to monitor to evaluate increased fatigue with pazopanib
Figure 5.3
Next systemic treatment choice for progressive disease
Figure 5.4
Chapter 6: Treatment of Patient with Comorbidities: Solitary Kidney
Treatment regimen for patient with solitary kidney
Figure 6.1
Treatment for disease progression
Table 6.2
Factors influencing treatment decision
Figure 6.3
Most important barriers to treatment
Figure 6.4
Confidence in managing this patient
Figure 6.5
Chapter 7: Summary
Appendix A: Survey Instrument

More United States Renal reports

Kidney Dialysis Centers by First Research, Inc.
Brief Excerpt from Industry Overview Chapter: Companies in this industry provide outpatient kidney dialysis services. Major companies include US-based DaVita and Dialysis Clinic, Inc., and Germany-based ...
United States Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters by GlobalData
United States Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters Summary GlobalData’s new report, “United States Nephrology and Urology ...
North America Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters by GlobalData
North America Nephrology and Urology Devices Market Outlook to 2018 - Incontinence Devices, Renal Dialysis Equipment and Lithotripters Summary GlobalData’s new report, “North America Nephrology and Urology ...
Kidney Dialysis Centers by First Research, Inc.
Brief Excerpt from Industry Overview Chapter: The US commercial kidney dialysis industry includes about 4,200 centers with combined annual revenue of about $18 billion. Major companies ...
See all reports like this >>

More United States reports

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Renal Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!